Jan A. Hillert

Jan A. Hillert's AcademicInfluence.com Rankings

Jan A. Hillert

Philosophy

#7329

World Rank

#10525

Historical Rank

Logic

#4388

World Rank

#5672

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Why Is Jan A. Hillert Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Jan A. Hillert's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis (2011) (2511)
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis (2013) (1170)
Variants conferring risk of atrial fibrillation on chromosome 4q25 (2007) (910)
The same sequence variant on 9p21 associates with myocardial infarction, abdominal aortic aneurysm and intracranial aneurysm (2008) (765)
Multiple Sclerosis Severity Score (2005) (642)
Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility (2019) (589)
HLA class II-associated genetic susceptibility in multiple sclerosis: a critical evaluation. (1991) (511)
Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial (2009) (499)
Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation (2001) (479)
A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke (2009) (466)
Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring (2007) (391)
CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms (2001) (366)
MHC2TA is associated with differential MHC molecule expression and susceptibility to rheumatoid arthritis, multiple sclerosis and myocardial infarction (2005) (346)
Variation in interleukin 7 receptor alpha chain (IL7R) influences risk of multiple sclerosis. (2007) (332)
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies. (2020) (308)
A high-density screen for linkage in multiple sclerosis. (2005) (308)
Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease. (2000) (289)
Risk variants for atrial fibrillation on chromosome 4q25 associate with ischemic stroke (2008) (284)
Class II HLA interactions modulate genetic risk for multiple sclerosis (2015) (262)
HLA‐DR15 is associated with lower age at onset in multiple sclerosis (2000) (258)
Primarily chronic progressive and relapsing/remitting multiple sclerosis: two immunogenetically distinct disease entities. (1989) (258)
Smoking and two human leukocyte antigen genes interact to increase the risk for multiple sclerosis. (2011) (256)
Overexpression of the Cytokine BAFF and Autoimmunity Risk (2017) (255)
Variation in interleukin 7 receptor α chain (IL7R) influences risk of multiple sclerosis (2007) (253)
Genome-wide association study of over 40,000 bipolar disorder cases provides new insights into the underlying biology (2021) (240)
Genetic variation in the KIF1B locus influences susceptibility to multiple sclerosis (2008) (203)
Cerebrospinal fluid CXCL13 in multiple sclerosis: a suggestive prognostic marker for the disease course (2011) (200)
HLA-A Confers an HLA-DRB1 Independent Influence on the Risk of Multiple Sclerosis (2007) (198)
High concurrent presence of disability in multiple sclerosis (2007) (188)
The Swedish MS registry – clinical support tool and scientific resource (2015) (160)
The expanding genetic overlap between multiple sclerosis and type I diabetes (2009) (157)
Epstein-Barr virus and multiple sclerosis: interaction with HLA (2011) (157)
Interferon regulatory factor 5 (IRF5) gene variants are associated with multiple sclerosis in three distinct populations (2008) (155)
Plasma levels of 24S-hydroxycholesterol in patients with neurological diseases (2000) (154)
The CTLA-4 gene is associated with multiple sclerosis (1999) (153)
Network-based multiple sclerosis pathway analysis with GWAS data from 15,000 cases and 30,000 controls. (2013) (149)
Mendelian randomization shows a causal effect of low vitamin D on multiple sclerosis risk (2016) (149)
Treatment decisions in multiple sclerosis — insights from real-world observational studies (2017) (148)
Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. (2004) (145)
Inflammation in multiple sclerosis: the good, the bad, and the complex (2002) (143)
Multiple sclerosis is associated with genes within or close to the HLA‐DR‐DQ subregion on a normal DR15, DQ6, Dw2 haplotype (1993) (141)
Smoking and multiple sclerosis susceptibility (2013) (141)
Effect of Smoking Cessation on Multiple Sclerosis Prognosis. (2015) (138)
Modest familial risks for multiple sclerosis: a registry-based study of the population of Sweden (2014) (138)
Optic neuritis (1998) (137)
Two genes encoding immune-regulatory molecules (LAG3 and IL7R) confer susceptibility to multiple sclerosis (2005) (136)
Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks (2018) (135)
Shift work at young age is associated with increased risk for multiple sclerosis (2011) (131)
Soluble IL7Rα potentiates IL-7 bioactivity and promotes autoimmunity (2013) (127)
The multiple sclerosis- and narcolepsy-associated HLA class II haplotype includes the DRB5*0101 allele. (1995) (126)
Sunlight is associated with decreased multiple sclerosis risk: no interaction with human leukocyte antigen‐DRB1*15 (2012) (124)
A meta-analysis of whole genome linkage screens in multiple sclerosis (2003) (122)
Human leukocyte antigen studies in multiple sclerosis (1994) (122)
Increased numbers of T cells recognizing multiple myelin basic protein epitopes in multiple sclerosis (1992) (120)
Evidence for a causal relationship between low vitamin D, high BMI, and pediatric-onset MS (2017) (118)
Diagnostic use of cerebral and extracerebral oxysterols (2004) (117)
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study (2020) (117)
Changes in human plasma levels of the brain specific oxysterol 24S-hydroxycholesterol during progression of multiple sclerosis (2002) (116)
Increased expression of caspase-1 and interleukin-18 in peripheral blood mononuclear cells in patients with multiple sclerosis (2004) (116)
The Multiple Sclerosis Genomic Map: Role of peripheral immune cells and resident microglia in susceptibility (2017) (113)
Refining genetic associations in multiple sclerosis (2008) (108)
Importance of early treatment initiation in the clinical course of multiple sclerosis (2017) (106)
Multiple sclerosis with and without CSF bands: Clinically indistinguishable but immunogenetically distinct (2006) (106)
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis (2011) (105)
Confirmation of association between multiple sclerosis and CYP27B1 (2010) (104)
Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis (2021) (103)
Different HLA-DRB1 allele distributions in distinct clinical subgroups of sarcoidosis patients (2010) (99)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (98)
Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort (2013) (96)
A longitudinal study of variations in and predictors of fatigue in multiple sclerosis (2008) (92)
Alcohol as a modifiable lifestyle factor affecting multiple sclerosis risk. (2014) (91)
APOE epsilon variation in multiple sclerosis susceptibility and disease severity (2006) (89)
Cytomegalovirus seropositivity is negatively associated with multiple sclerosis (2014) (89)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
Effects of early treatment with glatiramer acetate in patients with clinically isolated syndrome (2013) (87)
Apoptosis mediators FasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS (2000) (87)
Expression of B-cell-activating factor of the TNF family (BAFF) and its receptors in multiple sclerosis (2004) (86)
A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis (2002) (86)
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response (2017) (85)
Confounding effect of blood volume and body mass index on blood neurofilament light chain levels (2020) (82)
Familial effects on the clinical course of multiple sclerosis (2006) (82)
Hospital admission due to infections in multiple sclerosis patients (2013) (82)
Age Related Multiple Sclerosis Severity Score: Disability ranked by age (2016) (82)
The impact of HLA‐A and ‐DRB1 on age at onset, disease course and severity in Scandinavian multiple sclerosis patients (2007) (79)
A genome-wide scan and HCRTR2 candidate gene analysis in a European cluster headache cohort (2006) (79)
Evidence of linkage with HLA-DR in DRB1*15-negative families with multiple sclerosis. (2001) (78)
Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs (2013) (77)
MGAT5 alters the severity of multiple sclerosis (2010) (77)
Nicotine might have a protective effect in the etiology of multiple sclerosis (2013) (77)
In vivo TSPO imaging in patients with multiple sclerosis: a brain PET study with [18F]FEDAA1106 (2013) (77)
The importance of collecting structured clinical information on multiple sclerosis (2016) (75)
Functional neuroimaging in multiple sclerosis with radiolabelled glia markers: Preliminary comparative PET studies with [11C]vinpocetine and [11C]PK11195 in patients (2008) (74)
Evolution of microglial activation in ischaemic core and peri-infarct regions after stroke: A PET study with the TSPO molecular imaging biomarker [ 11 C]vinpocetine (2012) (73)
Molecular mimicry between Anoctamin 2 and Epstein-Barr virus nuclear antigen 1 associates with multiple sclerosis risk (2019) (73)
A rare variant of the TYK2 gene is confirmed to be associated with multiple sclerosis (2010) (72)
IL12A, MPHOSPH9/CDK2AP1 and RGS1 are novel multiple sclerosis susceptibility loci (2010) (72)
Tumor necrosis factor α-308 alleles in multiple sclerosis and optic neuritis (1995) (71)
Mutations in the promoter of adenylyl cyclase (AC)-III gene, overexpression of AC-III mRNA, and enhanced cAMP generation in islets from the spontaneously diabetic GK rat model of type 2 diabetes. (1998) (70)
Linkage and association analysis of genes encoding cytokines and myelin proteins in multiple sclerosis (1998) (69)
A sequence variant in ZFHX 3 on 16 q 22 associates with atrial fibrillation and ischemic stroke (2009) (68)
Spatial distribution of multiple sclerosis lesions in the cervical spinal cord (2019) (68)
Multiple sclerosis risk loci and disease severity in 7,125 individuals from 10 studies (2016) (68)
Lipid-specific immunoglobulin M in CSF predicts adverse long-term outcome in multiple sclerosis (2008) (68)
Cancer risk among patients with multiple sclerosis and their parents (2009) (67)
A genome-wide association study in progressive multiple sclerosis (2012) (67)
No association with germline T cell receptor β-chain gene alleles or haplotypes in Swedish patients with multiple sclerosis (1991) (67)
IL-22RA2 Associates with Multiple Sclerosis and Macrophage Effector Mechanisms in Experimental Neuroinflammation (2010) (66)
Blockade of chemokine signaling in patients with multiple sclerosis (2006) (66)
A Role for VAV1 in Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis (2009) (66)
Interferon beta preparations for the treatment of multiple sclerosis patients differ in neutralizing antibody seroprevalence and immunogenicity (2007) (65)
Does 77→G in PTPRC modify autoimmune disorders linked to the major histocompatibility locus? (2001) (64)
The Genetic Association of Variants in CD6, TNFRSF1A and IRF8 to Multiple Sclerosis: A Multicenter Case-Control Study (2011) (64)
Importance of Human Leukocyte Antigen (HLA) Class I and II Alleles on the Risk of Multiple Sclerosis (2012) (64)
RGMA and IL21R show association with experimental inflammation and multiple sclerosis (2010) (63)
Swedish natalizumab (Tysabri) multiple sclerosis surveillance study (2010) (62)
Multiple sclerosis registries in Europe – results of a systematic survey (2014) (62)
Risk for multiple sclerosis in relatives and spouses of patients diagnosed with autoimmune and related conditions (2009) (61)
In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent (2007) (61)
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients (2020) (60)
Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. (2015) (59)
Linkage and association analysis of susceptibility regions on chromosomes 5 and 6 in 106 Scandinavian sibling pair families with multiple sclerosis (1999) (59)
Multiple sclerosis clinical course and cardiovascular disease risk – Swedish cohort study (2014) (59)
APOE genotypes and disease severity in multiple sclerosis (2002) (58)
Oligoclonal Band Status in Scandinavian Multiple Sclerosis Patients Is Associated with Specific Genetic Risk Alleles (2013) (58)
Changes to anti-JCV antibody levels in a Swedish national MS cohort (2013) (57)
The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis (2001) (57)
A Proliferation‐inducing Ligand (APRIL) is Expressed by Astrocytes and is Increased in Multiple Sclerosis (2007) (57)
HLA-DRB1 and month of birth in multiple sclerosis (2009) (56)
Gene expression profiling in multiple sclerosis: A disease of the central nervous system, but with relapses triggered in the periphery? (2010) (54)
Intercellular adhesion molecule-1 K469E polymorphism: study of association with multiple sclerosis. (2003) (53)
High prevalence of sickness absence and disability pension among multiple sclerosis patients: a nationwide population-based study (2013) (53)
The HLA-Dw2 haplotype segregates closely with multiple sclerosis in multiplex families (1994) (53)
Long-term Cognitive Outcomes in Patients With Pediatric-Onset vs Adult-Onset Multiple Sclerosis. (2019) (52)
A common haplotype of the C‐C chemokine receptor 2 gene and HLA‐DRB1*0301 are independent genetic risk factors for Löfgren’s syndrome (2008) (52)
Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab (2011) (52)
JC Polyomavirus Infection Is Strongly Controlled by Human Leucocyte Antigen Class II Variants (2014) (52)
Visualising neuroinflammation in post-stroke patients: a comparative PET study with the TSPO molecular imaging biomarkers [11C]PK11195 and [11C]vinpocetine. (2012) (51)
Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid have less global and regional brain atrophy (2014) (51)
Increased levels of APRIL (A Proliferation-Inducing Ligand) mRNA in multiple sclerosis (2005) (51)
The Swedish motor neuron disease quality registry (2018) (51)
Modeling the cost-effectiveness of a new treatment for MS (natalizumab) compared with current standard practice in Sweden (2008) (51)
The thymus is a source of B-cell-survival factors–APRIL and BAFF–in myasthenia gravis (2006) (51)
PDE4D and ALOX5AP genetic variants and risk for Ischemic Cerebrovascular Disease in Sweden (2007) (50)
A rare P2X7 variant Arg307Gln with absent pore formation function protects against neuroinflammation in multiple sclerosis. (2015) (50)
Cytokine analysis in multiple sclerosis by competitive RT - PCR: A decreased expression of IL-10 and an increased expression of TNF-α in chronic progression (1999) (50)
Increased Serological Response Against Human Herpesvirus 6A Is Associated With Risk for Multiple Sclerosis (2019) (49)
Progression of non-age-related callosal brain atrophy in multiple sclerosis: a 9-year longitudinal MRI study representing four decades of disease development. (2007) (48)
Polymorphism analysis suggests that the gelatinase B gene is not a susceptibility factor for multiple sclerosis (2000) (48)
COVID-19 in people with multiple sclerosis: A global data sharing initiative (2020) (48)
Multiple sclerosis and psychiatric disorders: Comorbidity and sibling risk in a nationwide Swedish cohort (2014) (48)
Analysis of Nitric Oxide Synthase Genes in Cluster Headache (2002) (48)
Clinical course of multiple sclerosis: A nationwide cohort study (2017) (48)
Genetic susceptibility to MS: a second stage analysis in Canadian MS families (2001) (47)
Causal Effect of Genetic Variants Associated With Body Mass Index on Multiple Sclerosis Susceptibility (2017) (47)
Long-term disability progression of pediatric-onset multiple sclerosis (2019) (47)
An immunogenetic heterogeneity in multiple sclerosis. (1992) (46)
Association of rheumatoid arthritis with a dominant DR1/Dw4/Dw14 sequence motif, but not with T cell receptor beta chain gene alleles or haplotypes. (2010) (45)
CACNA1A Gene Polymorphisms in Cluster Headache (2001) (45)
Comparative effectiveness of rituximab relative to IFN-β or glatiramer acetate in relapsing-remitting MS from the Swedish MS registry (2018) (44)
Smoking and risk of treatment-induced neutralizing antibodies to interferon β-1a (2014) (44)
New data identify an increasing sex ratio of multiple sclerosis in Sweden (2014) (44)
Predicting risk of secondary progression in multiple sclerosis: A nomogram (2018) (44)
Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden. (2019) (43)
Reverse causality behind the association between reproductive history and MS (2014) (43)
Neutralising antibodies to interferon β in multiple sclerosis (2007) (42)
The interaction between smoking and HLA genes in multiple sclerosis: replication and refinement (2017) (41)
Human Leukocyte Antigen Genes and Interferon Beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis (2014) (41)
Mortality trends for multiple sclerosis patients in Sweden from 1968 to 2012 (2017) (41)
An immunogenetic heterogeneity in multiple sclerosis (1991) (41)
Maternal smoking during pregnancy and multiple sclerosis amongst offspring (2008) (41)
HLA-DRB1⁎15 and cerebrospinal-fluid-specific oligoclonal immunoglobulin G bands lower age at attainment of important disease milestones in multiple sclerosis (2009) (41)
Disability worsening among persons with multiple sclerosis and depression (2019) (41)
T‐cell receptor α chain germline gene polymorphisms in multiple sclerosis (1992) (41)
IL 12 A , MPHOSPH 9 / CDK 2 AP 1 and RGS 1 are novel multiple sclerosis susceptibility loci (2010) (41)
Multiple sclerosis registries in Europe - An updated mapping survey. (2019) (41)
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies. (2021) (40)
An angiotensin‐converting enzyme gene polymorphism suggests a genetic distinction between ischaemic stroke and carotid stenosis (1999) (39)
The Expression of VEGF-A Is Down Regulated in Peripheral Blood Mononuclear Cells of Patients with Secondary Progressive Multiple Sclerosis (2011) (39)
Modes of action of HLA-DR susceptibility specificities in multiple sclerosis. (2004) (39)
Smokers run increased risk of developing anti-natalizumab antibodies (2014) (39)
Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis (2015) (38)
Characterization of anti-natalizumab antibodies in multiple sclerosis patients (2013) (38)
CTLA4 dimorphisms and the multiple sclerosis phenotype (2002) (38)
Linkage analysis in multiple sclerosis of chromosomal regions syntenic to experimental autoimmune disease loci (2001) (38)
Associations of DMT therapies with COVID-19 severity in multiple sclerosis (2020) (37)
Upregulation of the apoptosis regulators cFLIP, CD95 and CD95 ligand in peripheral blood mononuclear cells in relapsing–remitting multiple sclerosis (2003) (36)
Alternative splicing of interleukin-7 (IL-7) and interleukin-7 receptor alpha (IL-7Rα) in peripheral blood from patients with multiple sclerosis (MS) (2010) (35)
Linkage analysis of HLA class II Genes in Swedish multiplex families with multiple sclerosis (1997) (35)
A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study (2016) (35)
Obesity interacts with infectious mononucleosis in risk of multiple sclerosis (2014) (35)
Use of a genetic isolate to identify rare disease variants: C7 on 5p associated with MS. (2009) (35)
An interleukin 1-receptor-antagonist gene polymorphism is not associated with multiple sclerosis (1996) (35)
Multiple sclerosis and risk of attempted and completed suicide – a cohort study (2016) (34)
Cognitive function is a major determinant of income among multiple sclerosis patients in Sweden acting independently from physical disability (2019) (34)
Genetic risk factors for pediatric-onset multiple sclerosis (2018) (34)
Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis (2010) (33)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2018) (33)
Lack of replication of interaction between EBNA1 IgG and smoking in risk for multiple sclerosis (2012) (33)
The Temporal Retinal Nerve Fiber Layer Thickness Is the Most Important Optical Coherence Tomography Estimate in Multiple Sclerosis (2017) (33)
Multiple sclerosis: a study of chemokine receptors and regulatory T cells in relation to MRI variables (2003) (33)
Germ-line polymorphism of TCR genes and disease susceptibility--fact or hypothesis? (1992) (33)
Genome-wide linkage screen of a consanguineous multiple sclerosis kinship (2003) (32)
Comparative analysis of first-year fingolimod and natalizumab drug discontinuation among Swedish patients with multiple sclerosis (2016) (32)
The genetics of multiple sclerosis and its experimental models (2008) (32)
Immunoglobulin gamma constant gene region polymorphisms in multiple sclerosis (1993) (31)
Costs of illness of multiple sclerosis in Sweden: a population-based register study of people of working age (2017) (31)
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. (2007) (30)
Earnings and Financial Compensation from Social Security Systems Correlate Strongly with Disability for Multiple Sclerosis Patients (2015) (30)
Association of Pre-Disease Body Mass Index With Multiple Sclerosis Prognosis (2018) (30)
The interleukin 23 receptor gene in multiple sclerosis: A case-control study (2008) (30)
Tumor necrosis factor alpha-308 alleles in multiple sclerosis and optic neuritis. (1995) (30)
A longitudinal observational study of brain atrophy rate reflecting four decades of multiple sclerosis: a comparison of serial 1D, 2D, and volumetric measurements from MRI images (2010) (30)
Shared genetic factors may not explain the raised risk of comorbid inflammatory diseases in multiple sclerosis (2012) (29)
High Levels of Epstein–Barr Virus Nuclear Antigen-1-Specific Antibodies and Infectious Mononucleosis Act Both Independently and Synergistically to Increase Multiple Sclerosis Risk (2020) (29)
Microsatellite polymorphisms in the gene promoter of monocyte chemotactic protein-3 and analysis of the association between monocyte chemotactic protein-3 alleles and multiple sclerosis development (1999) (29)
The long-term impact of early treatment of multiple sclerosis on the risk of disability pension (2018) (28)
Lipoprotein lipase gene polymorphisms in ischaemic stroke and carotid stenosis (1997) (28)
Two HLA class I genes independently associated with multiple sclerosis (2010) (28)
Psychiatric Diagnoses, Medication and Risk for Disability Pension in Multiple Sclerosis Patients; a Population-Based Register Study (2014) (27)
PECAM1, MPO and PRKAR1A at chromosome 17q21-q24 and susceptibility for multiple sclerosis in Sweden and Sardinia (2000) (27)
Mutation screening of the interferon-gamma gene as a candidate gene for multiple sclerosis. (1999) (27)
Systemic upregulation of CD40 and CD40 ligand mRNA expression in multiple sclerosis (2000) (27)
Genetic association analysis of the interleukin 7 gene (IL7) in multiple sclerosis (2007) (27)
Early clinical markers of aggressive multiple sclerosis. (2019) (27)
Multiple sclerosis lesions in motor tracts from brain to cervical cord: spatial distribution and correlation with disability. (2020) (27)
Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs (2004) (27)
HLA and MS (1993) (27)
Sources and level of income among individuals with multiple sclerosis compared to the general population: A nationwide population-based study (2015) (27)
Sick leave and disability pension before and after diagnosis of multiple sclerosis (2016) (26)
Lack of support for association between the KIF1B rs10492972[C] variant and multiple sclerosis (2010) (26)
Linkage analysis of a candidate region in Scandinavian sib pairs with multiple sclerosis reveals linkage to chromosome 17q (2000) (26)
Antibody‐mediated suppression of Vβ5.2/5.3+ T cells in multiple sclerosis: Results from an MRI‐monitored phase II clinical trial (2002) (26)
Co-morbidities increase the risk of disability pension among MS patients: a population-based nationwide cohort study (2014) (25)
Association and linkage analysis of candidate chromosomal regions in multiple sclerosis: indication of disease genes in 12q23 and 7ptr–15 (1999) (25)
Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta. (2010) (25)
Assess, compare and enhance the status of Persons with Multiple Sclerosis (MS) in Europe: a European Register for MS (2012) (25)
No association with HLA-DR, -DQ or -DP alleles in Guillain-Barré syndrome (1991) (25)
Non‐adherence to interferon‐beta therapy in Swedish patients with multiple sclerosis (2010) (24)
A NOTCH4 association with multiple sclerosis is secondary to HLA-DR*1501. (2004) (24)
Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: A study of the Swedish multiple sclerosis registry (2021) (23)
Optic neuritis: findings on MRI, CSF examination and HLA class II typing in 60 patients and results of a short-term follow-up (1994) (22)
Molecular cloning of a full-length cDNA for human type 3 adenylyl cyclase and its expression in human islets. (1999) (22)
Gene Expression Profiling in Cluster Headache: A Pilot Microarray Study (2006) (22)
Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans. (2006) (21)
ITGA4 polymorphisms and susceptibility to multiple sclerosis (2007) (21)
Increased Soluble 4‐1BB Ligand (4‐1BBL) Levels in Peripheral Blood of Patients with Multiple Sclerosis (2006) (21)
How does work disability of patients with MS develop before and after diagnosis? A nationwide cohort study with a reference group (2016) (21)
Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients (2003) (20)
The HLA-D region-associated MS-susceptibility genes may be located telomeric to the HLA-DP subregion. (1990) (20)
TGFβ regulates persistent neuroinflammation by controlling Th1 polarization and ROS production via monocyte‐derived dendritic cells (2016) (20)
The telltale scan: APOE ɛ4 in multiple sclerosis (2004) (20)
Genetically determined susceptibility to neurodegeneration is associated with expression of inflammatory genes (2006) (20)
The myelin basic protein gene in multiple sclerosis: identification of discrete alleles of a 1.3 kb tetranucleotide repeat sequence (1998) (19)
Factors associated with and long-term outcome of benign multiple sclerosis: a nationwide cohort study (2019) (19)
No linkage or association of the nitric oxide synthase genes to multiple sclerosis (2001) (19)
Prevalence of anti-drug antibodies against interferon beta has decreased since routine analysis of neutralizing antibodies became clinical practice (2012) (19)
Comparative study of four different assays for the detection of binding antibodies against interferon-β (2008) (18)
Comparing costs of illness of multiple sclerosis in three different years: A population-based study (2018) (18)
Differential expression, and genetic association, of CD58 in Swedish multiple sclerosis patients (2009) (18)
Rate of ventricular enlargement in multiple sclerosis: a nine-year magnetic resonance imaging follow-up study (2008) (18)
Age-dependent effects on the treatment response of natalizumab in MS patients (2015) (18)
A topological data analysis based classification method for multiple measurements (2019) (18)
Heterogeneity of sickness absence and disability pension trajectories among individuals with MS (2015) (18)
Costs and quality of life by disability among people with multiple sclerosis: a register-based study in Sweden (2018) (18)
Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network (2021) (18)
Genetic profile of ischemic cerebrovascular disease and carotid stenosis (2008) (18)
Distribution of HLA‐Dw2 in optic neuritis and multiple sclerosis indicates heterogeneity (1996) (18)
Analysis of an interferon-γ gene dinucleotide-repeat polymorphism in Nordic multiple sclerosis patients (2001) (18)
Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort (2014) (17)
Familial Cluster Headache. Is Atypical Cluster Headache in Family Members Part of the Clinical Spectrum? (2005) (17)
Cognitive function predicts work disability among multiple sclerosis patients (2019) (17)
The expression of BAFF‐binding receptors is not altered in multiple sclerosis or myasthenia gravis (2007) (17)
Longitudinal changes in sickness absence and disability pension, and associations between disability pension and disease-specific and contextual factors and functioning, in people with multiple sclerosis (2016) (17)
Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop neutralizing antibodies against interferon beta (2010) (17)
Validation of multiple sclerosis diagnoses in the Swedish National Patient Register (2019) (17)
Low sun exposure increases multiple sclerosis risk both directly and indirectly (2019) (17)
Conjugal multiple sclerosis (1992) (17)
Susceptibility to demyelinating polyneuropathy in plasma cell dyscrasia may be influenced by amino acid position 9 of the HLA-DRβ chain (1993) (16)
Genome-wide TDT analysis in a localized population with a high prevalence of multiple sclerosis indicates the importance of a region on chromosome 14q (2003) (16)
Association analysis of the LAG3 and CD4 genes in multiple sclerosis in two independent populations (2006) (16)
Exposure to anaesthetic agents does not affect multiple sclerosis risk (2013) (16)
HLA‐DR15 and age at onset in multiple sclerosis (2002) (16)
Pregnancy outcomes after exposure to interferon beta: a register-based cohort study among women with MS in Finland and Sweden (2020) (15)
Personal Income Before and After Diagnosis of Multiple Sclerosis. (2017) (15)
Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans (2012) (15)
Expression of IFN-γ, IL-4, and TGF-β in multiple sclerosis in relation to HLA-Dw2 phenotype and stage of disease (1995) (15)
Neutralizing antibodies against interferon beta: fluctuation is modest and titre dependent (2009) (15)
Earnings among people with multiple sclerosis compared to references, in total and by educational level and type of occupation: a population-based cohort study at different points in time (2019) (14)
High inbreeding in the Faroe Islands does not appear to constitute a risk factor for multiple sclerosis (2015) (14)
The SH2D2A gene and susceptibility to multiple sclerosis (2008) (14)
Treatment with P2 protein peptide 57–81 by nasal route is effective in Lewis rat experimental autoimmune neuritis (1998) (14)
Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations (2017) (13)
Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk (2020) (13)
Income in Multiple Sclerosis Patients with Different Disease Phenotypes (2017) (13)
Variability in the CIITA gene interacts with HLA in multiple sclerosis (2014) (13)
Retinal nerve fiber layer thickness associates with cognitive impairment and physical disability in multiple sclerosis. (2019) (13)
Sharing of a conserved haplotype suggests a susceptibility gene for multiple sclerosis at chromosome 17p11 (2002) (13)
Familial risk of early- and late-onset multiple sclerosis: a Swedish nationwide study (2018) (12)
Multiple sclerosis: occurrence of myelin basic protein peptide‐reactive T cells in healthy family members (1994) (12)
The long-term impact of multiple sclerosis on the risk of divorce. (2018) (12)
Impact of cerebrospinal-fluid oligoclonal immunoglobulin bands and HLA-DRB1 risk alleles on brain magnetic-resonance-imaging lesion load in Swedish multiple sclerosis patients (2013) (12)
Absence of linkage with the neuronal nitric oxide synthase (NOS1) gene in 41 multiplex Swedish MS families (1998) (12)
A ‘‘Candidate-Interactome’’ Aggregate Analysis of Genome-Wide Association Data in Multiple Sclerosis (2013) (12)
The telltale scan: APOE epsilon4 in multiple sclerosis. (2004) (11)
The association between multiple sclerosis and pain medications (2018) (11)
Accurate classification of secondary progression in multiple sclerosis using a decision tree (2020) (11)
Decreased levels of CD95 and caspase-8 mRNA in multiple sclerosis patients with gadolinium-enhancing lesions on MRI (2003) (11)
No influence on disease progression of non-HLA susceptibility genes in MS (2011) (11)
No linkage or association of a VNTR marker in the junction region of the immunoglobulin heavy chain genes in multiple sclerosis. (1997) (11)
Decreased mRNA expression of TNF‐α and IL‐10 in non‐stimulated peripheral blood mononuclear cells in myasthenia gravis (2000) (11)
The association between exposure to interferon-beta during pregnancy and birth measurements in offspring of women with multiple sclerosis (2019) (11)
Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. (2008) (11)
Multiple sclerosis in a family on the Faroe Islands (2010) (10)
Healthcare, Sickness Absence, and Disability Pension Cost Trajectories in the First 5 Years After Diagnosis with Multiple Sclerosis: A Prospective Register-Based Cohort Study in Sweden (2019) (10)
The 'Immunomodulation and Multiple Sclerosis Epidemiology' (IMSE) study : a Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of natalizumab (Tysabri) (2012) (10)
Analysis of an interferon-gamma gene dinucleotide-repeat polymorphism in Nordic multiple sclerosis patients. (2001) (10)
The narcolepsy-associated DRw15,DQw6,Dw2 haplotype has no unique HLA-DQA or -DQB restriction fragments and does not extend to the HLA-DP subregion. (1990) (10)
Determinants of quality of life in pediatric- and adult-onset multiple sclerosis (2019) (10)
Multiple sclerosis: Postlinkage genetics (2006) (10)
Refining the linkage analysis on chromosome 10 in 449 sib-pairs with multiple sclerosis (2003) (10)
Plasma protein profiling reveals candidate biomarkers for multiple sclerosis treatment (2019) (9)
All‐cause mortality following a cancer diagnosis amongst multiple sclerosis patients: a Swedish population‐based cohort study (2015) (9)
Characterization of annual disease progression of multiple sclerosis patients: A population-based study (2018) (9)
Stressful life events are associated with the risk of multiple sclerosis (2020) (9)
Rituximab is an acceptable alternative to ocrelizumab for treating multiple sclerosis – Yes (2018) (9)
Mortality following a brain tumour diagnosis in patients with multiple sclerosis (2013) (9)
Long-term Socioeconomic Outcomes Associated With Pediatric-Onset Multiple Sclerosis. (2021) (9)
A methylenetetrahydrofolate reductase gene polymorphism in multiple sclerosis (1997) (8)
CANCER RISK AMONG PATIENTS WITH MULTIPLE SCLEROSIS AND THEIR PARENTS. Authors' reply (2010) (8)
Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655 (2011) (8)
A rare P 2 X 7 variant Arg 307 Gln with absent pore formation function protects against neuroin fl ammation in multiple sclerosis (2015) (8)
Cigarette smoking patterns preceding primary Sjögren’s syndrome (2020) (8)
Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network (2021) (8)
Common CCR 5 polymorphism in stroke: the CCR 5 delta32 polymorphism differentiates cardioembolism from other aetiologies of ischaemic cerebrovascular diseases. (2009) (8)
An association study of two functional promotor polymorphisms in the myeloperoxidase (MPO) gene in multiple sclerosis (2007) (8)
Expression of IFN-gamma, IL-4, and TGF-beta in multiple sclerosis in relation to HLA-Dw2 phenotype and stage of disease. (1995) (8)
Oligoclonal band phenotypes in MS differ in their HLA class II association, while specific KIR ligands at HLA class I show association to MS in general (2014) (8)
Diagnosis-specific sickness absence and disability pension before and after multiple sclerosis diagnosis: An 8-year nationwide longitudinal cohort study with matched references. (2020) (7)
Smoking and Epstein–Barr virus infection in multiple sclerosis development (2020) (7)
One-dimensional-ratio measures of atrophy progression in multiple sclerosis as evaluated by longitudinal magnetic resonance imaging (2009) (7)
Systematic Review of the Socioeconomic Consequences in Patients With Multiple Sclerosis With Different Levels of Disability and Cognitive Function (2022) (7)
In the coming year we should abandon interferons and glatiramer acetate as first line therapy for MS: No (2013) (7)
Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden (2017) (7)
Clinical course of multiple sclerosis and labour‐force absenteeism: a longitudinal population‐based study (2019) (7)
Socioeconomic consequences of multiple sclerosis—A systematic literature review (2021) (7)
The genetics of multiple sclerosis. (2010) (6)
Interferon beta treatment of multiple sclerosis increases serum interleukin-7 (2014) (6)
Types of working-life sequences among people recently diagnosed with multiple sclerosis in Sweden: a nationwide register-based cohort study (2020) (6)
Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset (2022) (6)
T-cell receptor alpha chain germline gene polymorphisms in multiple sclerosis. (1992) (6)
Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis (2022) (6)
CTLA‐4 dimorphisms in gammopathy‐associated peripheral neuropathy (1999) (6)
Reduction in Cognitive Processing Speed Surrounding Multiple Sclerosis Relapse (2022) (6)
Importance of early treatment decisions on future income of multiple sclerosis patients (2020) (6)
Is disability pension a risk indicator for future need of psychiatric healthcare or suicidal behavior among MS patients- a nationwide register study in Sweden? (2015) (6)
Multiple Sclerosis Patients with Markedly Low Intrathecal Antibody Response in Sri Lanka (2018) (6)
Appendicectomy and multiple sclerosis risk (2011) (6)
Increased Rate of Hospitalisation for COVID-19 Amongst Rituximab Treated Multiple Sclerosis Patients: A Study of the Swedish MS Registry (2021) (5)
Overweight/obesity in young adulthood interacts with aspects of EBV infection in MS etiology (2020) (5)
Multiple sclerosis and risk of completed and attempted suicide - a national cohort study (2015) (5)
Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis (2020) (5)
Patients with High-Disease-Activity Relapsing-Remitting Multiple Sclerosis in Real-World Clinical Practice: A Population-Based Study in Sweden. (2019) (5)
Factors affecting the risk of relapsing-onset and progressive-onset multiple sclerosis (2021) (5)
Depression and multiple sclerosis: A bidirectional Mendelian randomisation study (2021) (5)
Linkage analysis suggests a region of importance for multiple sclerosis in 3p14–13 (2001) (5)
Multiple sclerosis treatment effects on plasma cytokine receptor levels. (2017) (5)
Cost-of-Illness Progression Before and After Diagnosis of Multiple Sclerosis: A Nationwide Register-Based Cohort Study in Sweden of People Newly Diagnosed with Multiple Sclerosis and a Population-Based Matched Reference Group (2021) (5)
HLA-Dw2 in multiple sclerosis: A world-wide association and a close segregation with disease in multiplex families (1993) (5)
Analysis of a CD40 ligand dinucleotide microsatellite in multiple sclerosis. (2002) (5)
HLA-A(∗)02, gender and tobacco smoking, but not multiple sclerosis, affects the IgG antibody response against human herpesvirus 6. (2014) (5)
Updated Results of the COVID-19 in MS Global Data Sharing Initiative (2022) (5)
Smoking Attributable Risk in Multiple Sclerosis (2022) (5)
A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3) (2017) (5)
Cerebrospinal fluid oligoclonal immunoglobulin gamma bands and long-term disability progression in multiple sclerosis: a retrospective cohort study (2021) (5)
Costs of illness progression for different multiple sclerosis phenotypes: a population-based study in Sweden (2019) (5)
The narcolepsy-associatedDRw15, DQw6, Dw2 haplotype has no uniqueHLA-DQA or -DQB restriction fragments and does not extend to theHLA-DP subregion (2005) (5)
[Early immunotherapy in MS reduces the risk of later disability. The secondary progressive course is delayed, according to a study with virtual placebo]. (2007) (4)
Socioeconomic status and multiple sclerosis outcome (2020) (4)
Low fish consumption is associated with a small increased risk of MS (2020) (4)
Pain and Painkiller Use Among Multiple Sclerosis Patients in Sweden (2017) (4)
Impression of Clinical Worsening Fails to Predict Interferon-β Neutralizing Antibody Status (2008) (4)
No evidence of IL21 association with multiple sclerosis in a Swedish population. (2011) (4)
Corrigendum to “Linkage disequilibrium screening for multiple sclerosis implicates JAG1 and POU2AF1 as susceptibility genes in Europeans” [J. Neuroimmunol. 179 (2006) 108–116] (2007) (4)
DRB1–environment interactions in multiple sclerosis etiology: results from two Swedish case–control studies (2021) (4)
A 10-year population-based study of people with multiple sclerosis in Stockholm, Sweden: use of and satisfaction with care and the value of different factors in predicting use of care (2015) (4)
P.1.k.021 Multiple sclerosis and psychiatric disorders: comorbidity and sibling risk in a nationwide Swedish cohort (2014) (4)
Genetic analysis of the isolated Faroe Islands reveals SORCS3 as a potential multiple sclerosis risk gene (2016) (4)
The External Validity of Mapping MSIS-29 on EQ-5D Among Individuals With Multiple Sclerosis in Sweden (2017) (4)
Reply: Shared environmental effects on multiple sclerosis susceptibility: conflicting evidence from twin studies. (2014) (4)
The influence of immunomodulatory treatment on the clinical course of multiple sclerosis. (2015) (4)
High antibody levels against human herpesvirus-6A interact with lifestyle factors in multiple sclerosis development (2021) (3)
Comparison of the proportions of Secondary Progressive Multiple Sclerosis between three registries within the SPMS Research Collaboration Network (3977) (2020) (3)
Aggressive form of multiple sclerosis can be predicted early after disease onset (2019) (3)
A comparative study of teriflunomide and dimethyl fumarate within the Swedish MS Registry (2021) (3)
HLA and Neurological Diseases (2000) (3)
A follow-up study of Nordic multiple sclerosis candidate gene regions (2007) (3)
Similar familial risk in multiple sclerosis subgroups (2017) (3)
Considerations for Subgroups and Phenocopies in Complex Disease Genetics (2013) (3)
Prevalence of adverse pregnancy outcomes after exposure to interferon beta prior to or during pregnancy in women with MS: Stratification by maternal and newborn characteristics in a register-based cohort study in Finland and Sweden. (2020) (3)
Cerebrospinal fluid markers in incident pediatric-onset multiple sclerosis: a nationwide study (2021) (3)
The influence of human leukocyte antigen-DRB1*15:01 and its interaction with smoking in MS development is dependent on DQA1*01:01 status (2020) (3)
Neurofilament light chain as a marker for cortical atrophy in multiple sclerosis without radiological signs of disease activity (2021) (2)
Sharing of a conserved haplotype suggests a susceptibility gene for multiple sclerosis at chromosome 17p (1998) (2)
Multiple sclerosis: A modifying influence of HLA class I in an HLA class II associated autoimmune disease (1998) (2)
Bariatric and metabolic surgery in patients with morbid obesity and multiple sclerosis - a nationwide, matched cohort study. (2021) (2)
Early vs. late treatment initiation in multiple sclerosis and its impact on cost of illness: A register-based prospective cohort study in Sweden (2022) (2)
Similar familial risk in multiple sclerosis subgroups Introduction (2017) (2)
State of the Art and Future Challenges in Multiple Sclerosis Research and Medical Management: An Insight into the 5th International Porto Congress of Multiple Sclerosis (2020) (2)
Cost-of-illness trajectories among people with multiple sclerosis by comorbidity: A register-based prospective study in Sweden (2020) (2)
Polymorphism in MS (1992) (2)
Prescribed psychiatric medication among multiple sclerosis patients before and after disability pension: a register study with matched controls (2016) (2)
Retinal nerve fibre layer thickness associates with cognitive impairment and physical disability in multiple sclerosis (2017) (2)
MYO9B polymorphisms in multiple sclerosis (2009) (2)
A multiple sclerosis disease progression measure based on cumulative disability (2021) (2)
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network (2022) (2)
Validating the diagnosis of multiple sclerosis using Swedish administrative data in Värmland County (2021) (1)
[Every fifth case of multiple sclerosis is familial]. (2014) (1)
Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden (2021) (1)
A Comparison of Brain Age Estimation And Brain Parenchymal Fraction as Imaging Markers in Multiple Sclerosis (2022) (1)
Anti-JC Virus Antibody Titer Changes during Natalizumab Treatment in a Swedish MS Cohort (P02.139) (2012) (1)
CSF1R Gene Screening In A Cohort Of 218 Primary Progressive Multiple Sclerosis (PPMS) Patients From The Norwegian And Swedish National PPMS Registries (S34.009) (2014) (1)
COVID‐19 clinical outcomes and DMT of MS patients and population‐based controls (2022) (1)
Novel CSF biomarkers NFL and CXCL 13,-relationship with other CSF parameters and disease variables in MS (P1.385) (2017) (1)
Multiple sclerosis and risk of young-adult-onset Hodgkin lymphoma (2016) (1)
Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β (2022) (1)
HLA AND MS. AUTHOR'S REPLY (1993) (1)
PND19 ECONOMIC EVALUATION OF INTERFERON-Â-IB IN THE TREATMENT OF PATIENTS WITH A CLINICALLY ISOLATED SYNDROME (CIS) (2007) (1)
Season of birth is associated with multiple sclerosis and disease severity (2021) (1)
Comparison of employment among people with Multiple Sclerosis across Europe (2022) (1)
MS genetics: recent Scandinavian efforts. (2000) (1)
ND2 MODELING THE COST-EFFECTIVENESS OF A NEW TREATMENT FOR MS (NATALIZUMAB) COMPARED TO CURRENT STANDARD PRACTICE IN SWEDEN (2007) (1)
A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and efficacy of natalizumab (2015) (1)
Copy number variations across the blood–brain barrier in multiple sclerosis (2022) (1)
Gender ratio in the National Swedish MS Register (2008) (1)
Accurate classification of secondary progression in multiple sclerosis (2020) (1)
236 A search for susceptibility genes in late-onset Alzheimer's disease (1996) (1)
Income and cognitive impairment among multiple sclerosis patients (2016) (1)
A Swedish Nationwide study of the long-term effectiveness and safety of teriflunomid based on data from the Swedish "Immunomodulation and Multiple Sclerosis Epidemiology" Study (IMSE 4) (2019) (1)
Parkinson ’ s disease and movement disorders : expanding the boundaries of current practice (2010) (0)
Comparing indirect costs of multiple sclerosis in three different years : A population-based study (2016) (0)
Genetic variants are major determinants of cerebrospinal fluid antibody levels in multiple sclerosis (2015) (0)
IRF5 implicated in the pathogenesis of multiple sclerosis. (2012) (0)
[High societal costs of brain diseases. Extremely small resources allocated to research on prevention and treatment]. (2007) (0)
Association between early treatment of multiple sclerosis and patient-reported outcomes: a nationwide observational cohort study (2022) (0)
Genetic load in eleven distantly related individuals from an MS high risk area (2015) (0)
Emerging Oral Medications for Multiple Sclerosis (2012) (0)
P100 Soluble IL7Ra isoform modulates IL7 signalling and homeostasis (2012) (0)
Is there an HLA-associated non-HLA “Narcolepsy gene” (1994) (0)
generation immunomodulating drugs Time to secondary progression in patients with multiple sclerosis who were treated with first (2013) (0)
Identification of novel genetic risk loci determine fetal outcome in congenital heart block (2012) (0)
Author response: Disability worsening among persons with multiple sclerosis and depression: A Swedish cohort study (2020) (0)
PA P ER A topological data analysis based classi cation method for multiple measurements (2019) (0)
Real world experience of fingolimod after switching multiple sclerosis (MS) therapy; focus on natalizumab naive and experienced persons with MS, respectively (2016) (0)
Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations (2017) (0)
[Wanted: families with multiple sclerosis]. (1994) (0)
National Swedish MS Register Based Study: the Symbol Digit Modalities Test as a predictor of work disability (P3.222) (2015) (0)
Investigation of the Effect of Human Leukocyte Antigen on the Development of Neutralizing Antibodies in Interferon-beta Treated Patients with Multiple Sclerosis (*The First Three Authors Contributed Equally to This Work) (P05.121) (2012) (0)
Re: Declines in the diagnosis of primary progressive MS—A critical change in phenotype or critical measurement error? (2017) (0)
A candidate gene approach in MS based on the Rega model (2000) (0)
Earnings among people with multiple sclerosis in Sweden, by education and occupation (2019) (0)
Smoking and Epstein–Barr virus infection in multiple sclerosis development (2020) (0)
T cell receptor α and β chain gene RFLPs in multiple sclerosis (1991) (0)
PND54 COST-OF-ILLNESS TRAJECTORIES AMONG NEWLY DIAGNOSED MS PATIENTS TREATED WITH INTERFERONS, GLATIRAMER ACETATE, OR NATALIZUMAB: HEALTHCARE, SICKNESS ABSENCE, AND DISABILITY PENSION COSTS IN SWEDEN (2019) (0)
Topological data analysis to identify subgroups of multiple sclerosis patients with faster disease progression (2018) (0)
Self-reported restrictions in different life domains and associated factors among people with multiple sclerosis in Sweden. (2023) (0)
The Dw2 association in multiple sclerosis extends to the DRB5 locus (1994) (0)
Costs and disability among multiple sclerosis patients: A Swedish register-based study (2017) (0)
A multicenter, open label, non-comparative trial investigating the recovering of IFN-beta efficacy in breakthrough relapsing-remitting multiple sclerosis patients with neutralizing IFN-beta antibodies (RECOVER) (2008) (0)
Cigarette smoking is a risk factor for developing primary Sjögren's syndrome with Ro/SSA and La/SSB autoantibodies (2018) (0)
gene dinucleotide-repeat polymorphism in Nordic multiple sclerosis patients γ Analysis of an interferon- (2014) (0)
Implication of DNA methylation changes at chromosome 1q21.1 in the brain pathology of Primary Progressive Multiple Sclerosis (2022) (0)
COVID-19–Related Enhancement for the COMBAT-MS Study (2023) (0)
A swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (IMSE 3) for patients treated at least 24 months (2019) (0)
Trajectories of disease-modifying therapies and associated sickness absence and disability pension among 1923 people with multiple sclerosis in Sweden. (2022) (0)
Long Term, Registry-Based, Prospective, Post-Authorization Safety Study Evaluating Adverse Events of Special Interest in Patients with Highly Active Relapsing Multiple Sclerosis Newly Started on Cladribine Tablets − CLARION (2020) (0)
O06-5 Shift work at young age is associated with increased risk for multiple sclerosis (2016) (0)
Multiple sclerosis in a family on the Faroe Islands (2010) (0)
How do multiple sclerosis patients’ sickness absence and disability pension level change over time? (2014) (0)
PND80 Patterns of Working Life Sequences Among People Recently Diagnosed with MS in Sweden: A Nationwide Register-Based Longitudinal Cohort Study (2020) (0)
IN29-TU-01 Etiological factors in multiple sclerosis (2009) (0)
Entering a new phase of multiple sclerosis genetic epidemiology (2011) (0)
Psychiatric Drug Consumption Among Multiple Sclerosis Patients Before and After Disability Pension; a Controlled Register Study (2015) (0)
Varicella zoster virus IgG titers correlate with multiple sclerosis (2012) (0)
Proportion and characteristics of secondary progressive multiple sclerosis in five European registries using objective classifiers (2023) (0)
MS-VÅRDEN INTENSIFIERAS (1996) (0)
HLA Genes and Interferon-beta Preparations Influence Risk of Developing Neutralizing Anti-Drug Antibodies in Multiple Sclerosis (P1.213) (2014) (0)
Incidence Trends of Multiple Sclerosis Disability Milestones: A Nationwide Population-Based Cohort Study in Sweden (P2.145) (2016) (0)
A Swedish real word study of the long-term effectiveness and safety of fingolimod (IMSE 2) with focus on patients treated at least 48 months (2019) (0)
PND35 - HEALTHCARE, SICKNESS ABSENCE, AND DISABILITY PENSION COST TRAJECTORIES IN FIVE YEARS FOLLOWING MS DIAGNOSIS: REGISTER-BASED PROSPECTIVE COHORT STUDIES IN SWEDEN (2018) (0)
Anti-Natalizumab Antibodies in Patients with Multiple Sclerosis (2012) (0)
A family with multiple sclerosis on the Faroe Islands (2009) (0)
Abstract 2921: Genome-wide Association Reveals Sequence Variants on 4q25 that Affect the Risk of Atrial Fibrillation and Stroke (2007) (0)
Molecular mimicry between the autoantigen Anoctamin 2 and Epstein Barr virus nuclear antigen 1 associates with increased risk for multiple sclerosis (2018) (0)
The DQB1*03:02 Genotype and Treatment for Pain in People With and Without Multiple Sclerosis (2020) (0)
Next generation sequencing of SORCS3 in multiple sclerosis patients and healthy controls from the isolated Faroe Islands (2016) (0)
Sick Leave and Disability Pension in Patients with Multiple Sclerosis: A Longitudinal, Observational Study (P2.192) (2016) (0)
Genetic risk factors are associated with cerebrospinal fluid measures in multiple sclerosis (2014) (0)
Observed associations between indicators of socioeconomic status and risk of multiple sclerosis in Sweden are explained by a few lifestyle‐related factors (2023) (0)
Influence of co-morbidity on MS patients’ risk for disability pensionPetter Tinghög (2013) (0)
Excess costs of multiple sclerosis: a register-based study in Sweden (2022) (0)
Genetic Variants in Iron Metabolism impact Disease Progression in MS through HIF1A (S9.006) (2023) (0)
Trajectories of sickness absence and disability pension days among people with multiple sclerosis by type of occupation (2021) (0)
Oligoclonal Immunoglobulin Gamma Bands in the Cerebrospinal Fluid and Risk of Conversion to Secondary Progress in Multiple Sclerosis (P1.370) (2016) (0)
Association between exposure to combustion-related air pollution and multiple sclerosis risk. (2023) (0)
Comparing the Safety of Medicines to Treat MS during the COVID-19 Pandemic (2023) (0)
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci | NOVA. The University of Newcastle's Digital Repository (2011) (0)
Abstracts of the 14th Congress of the EFNS (European Federation of Neurological Societies). Geneva, Switzerland. September 26-28, 2010. (2010) (0)
The Association Between Disease Activity and Health-Related Quality of Life in RRMS Patients (2017) (0)
Replication phase of a whole-genome association study in progressive forms of multiple sclerosis (2009) (0)
Predicting conversion to secondary progressive multiple sclerosis using a clinical decision tree (2016) (0)
Title: Automatic segmentation of the spinal cord and intramedullary multiple sclerosis lesions with convolutional neural networks Authors: (2018) (0)
Influence of oral tobacco versus smoking on multiple sclerosis disease activity and progression (2023) (0)
2.K. Round table: Navigational health literacy. Perspectives from Austria, Germany and Switzerland (2022) (0)
Number of OCBs in CSF at diagnosis timepoint,— predictor of long term radiological outcome in MS? (2014) (0)
neutralizing antibodies against interferon beta Multiple sclerosis patients lacking oligoclonal bands in the cerebrospinal fluid are less likely to develop (0)
Self‐employment, sickness absence, and disability pension in multiple sclerosis (2022) (0)
Investigation of C5a in multiple sclerosis - two different strategies at the DNA level (2004) (0)
The influence of host genetics on Epstein-Barr virus specific antibody levels in multiple sclerosis patients and controls (2012) (0)
Segmental Sharing Analysis of Multiple Sclerosis Patients and Controls From the Faroe Islands (P2.220) (2015) (0)
Rituximab in multiple sclerosis; data from the swedish MS registry. (2016) (0)
Heterogeneity of optic neuritis by HLA-DR DQ genotyping (1994) (0)
KIF1B, the First Neuronally Expressed Gene Associated with Multiple Sclerosis (2009) (0)
[Intensifying the care of MS-patients]. (1996) (0)
Long-term Survival in Multiple Sclerosis is Improving (P5-3.011) (2023) (0)
Web figure 1 (2013) (0)
Linkage found to chromosome 17q in Scandinavian sib pairs with multiple sclerosis (2000) (0)
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort. (2022) (0)
ECTRIMS 2021 – Late Breaking News Oral Presentations (2021) (0)
Predictors of Disability Extremes in Patients with Multiple Sclerosis Treated with Interferon-beta Using the Swedish MS Registry (P4.188) (2014) (0)
MS and the association of the DQB1*0302 allele with pain (2019) (0)
A topological data analysis based classification method for multiple measurements (2020) (0)
The IMSE 2 study : a Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of fingolimod (2015) (0)
Association between brain volume and disability over time in multiple sclerosis (2022) (0)
Experimental Neuroinflammation and Macrophage Effector Mechanisms in Associates with Multiple Sclerosis IL-22RA2 (2010) (0)
Oligoclonal Immunoglobulin Gamma Bands and Long-Term Disability Progression in Multiple Sclerosis: A Retrospective Cohort Study (2021) (0)
POLYMORPHISM IN MS. REPLY (1992) (0)
Hillert standard practice in Sweden Modeling the cost-effectiveness of a new treatment for MS ( natalizumab ) compared with current (2008) (0)
Tonsillectomy and bacterial serum antibodies in multiple sclerosis patients: A case-control study (1991) (0)
The Effect of Different National Treatment Strategies on Disability Outcome in Relapsing-Remitting Multiple Sclerosis: A Propensity Score Adjusted Comparison between Denmark and Sweden (2021) (0)
Spasticity treatment patterns among people with multiple sclerosis: a Swedish cohort study (2022) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Jan A. Hillert?

Jan A. Hillert is affiliated with the following schools:

Karolinska Institute

Jan A. Hillert's Academic­Influence.com Rankings

Why Is Jan A. Hillert Influential?

Jan A. Hillert's Published Works

Published Works

What Schools Are Affiliated With Jan A. Hillert?

Jan A. Hillert's AcademicInfluence.com Rankings